Literature DB >> 3985991

Structure-activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin, in vitro.

E Lacey, T R Watson.   

Abstract

The structure-activity relationships of thirty-two methyl (5(6)-substituted benzimidazol-2yl) carbamates as inhibitors of the rate of polymerisation of mammalian tubulin have been investigated. The size or some colinear physico-chemical characteristic of the substituent in the 5 (or 6)-position has a profound effect on potency. The presence of branching with or without a commensurate increase in the polarity of the 5(6)-substituent adjacent to the benzimidazole ring (alpha-position) resulted in a loss of activity. The nature of the overall site, as reflected by the quantitative models, could relate to either the hydrophobicity or molar volume of the 5 (or 6)-substituents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3985991     DOI: 10.1016/0006-2952(85)90611-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer.

Authors:  Le Zhang; Milana Bochkur Dratver; Taha Yazal; Kevin Dong; Andrea Nguyen; Garrett Yu; Amy Dao; Michael Bochkur Dratver; Sara Duhachek-Muggy; Kruttika Bhat; Claudia Alli; Frank Pajonk; Erina Vlashi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-09-07       Impact factor: 7.038

2.  Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.

Authors:  Ren-Yuan Bai; Verena Staedtke; Colette M Aprhys; Gary L Gallia; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2011-07-15       Impact factor: 12.300

3.  Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.

Authors:  Christopher Ma; Johnson Tran; Frank Gu; Roxanna Ochoa; Catherine Li; David Sept; Karl Werbovetz; Naomi Morrissette
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

4.  Biological Evaluation of a Potential Anticancer Agent Methyl N-[5-(3'-Iodobenzoyl)-1H-Benzimidazol-2-yl]Carbamate.

Authors:  Zbigniew P Kortylewicz; Don W Coulter; Janina Baranowska-Kortylewicz
Journal:  Cancer Biother Radiopharm       Date:  2019-11-05       Impact factor: 3.099

5.  Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642).

Authors:  Desirée Hao; Jinee D Rizzo; Stephanie Stringer; Rodney V Moore; Jennifer Marty; Daniel L Dexter; Gina L Mangold; James B Camden; Daniel D Von Hoff; Steven D Weitman
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

6.  2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site.

Authors:  R J D'Amato; C M Lin; E Flynn; J Folkman; E Hamel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

7.  Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication.

Authors:  Nilambra Dogra; Tapas Mukhopadhyay
Journal:  J Biol Chem       Date:  2012-06-28       Impact factor: 5.157

8.  Carbendazim inhibits cancer cell proliferation by suppressing microtubule dynamics.

Authors:  Mythili Yenjerla; Corey Cox; Leslie Wilson; Mary Ann Jordan
Journal:  J Pharmacol Exp Ther       Date:  2008-11-10       Impact factor: 4.030

9.  Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice.

Authors:  Anahid Ehteda; Peter Galettis; Krishna Pillai; David L Morris
Journal:  BMC Cancer       Date:  2013-02-23       Impact factor: 4.430

10.  Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways.

Authors:  Nilambra Dogra; Ashok Kumar; Tapas Mukhopadhyay
Journal:  Sci Rep       Date:  2018-08-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.